This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...

Полное описание

Библиографические подробности
Главные авторы:	Ryder, R, Holman, R, Gwilt, M
Формат:	Conference item
Опубликовано:	Association of British Clinical Diabetologists 2016

Схожие документы

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
по: Holman, R, и др.
Опубликовано: (1987)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
по: André J. Scheen
Опубликовано: (2021-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
по: Herlihy, O, и др.
Опубликовано: (2000)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
по: Cull, C, и др.
Опубликовано: (2000)

Sulphonylureas and hypoglycaemia.
по: Ferner, R, и др.
Опубликовано: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
по: Eeley, E, и др.
Опубликовано: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
по: Matthews, DR, и др.
Опубликовано: (1998)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
по: Huri, H.Z., и др.
Опубликовано: (2010)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
по: Eeley, E, и др.
Опубликовано: (1996)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
по: Misra, S, и др.
Опубликовано: (2018)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
по: Turner, R, и др.
Опубликовано: (1998)

New uses for old drugs: neonatal diabetes and sulphonylureas.
по: Ashcroft, F
Опубликовано: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
по: Peter Proks
Опубликовано: (2013-06-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
по: Matthews, DR, и др.
Опубликовано: (1998)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
по: Rachman, J, и др.
Опубликовано: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
по: Woodcock, A, и др.
Опубликовано: (2007)

Should I believe all the truths?
по: Greenberg, A
Опубликовано: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
по: Pearson, E, и др.
Опубликовано: (2007)

Stem cells in cancer : should we believe or not? /
по: Grande, Enrique, и др.
Опубликовано: (2014)

Sulphonylureas and the rise and fall of beta-cell function
по: Matthews, DR, и др.
Опубликовано: (2005)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
по: Rashida Vasanwala MD (Paeds), MRCPCH (UK), и др.
Опубликовано: (2010-06-01)

The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
по: N. A. Chernikova, и др.
Опубликовано: (2022-10-01)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
по: Degli Esposti L, и др.
Опубликовано: (2014-10-01)

Interactions between nicorandil and sulphonylureas: a structural basis.
по: Reimann, F, и др.
Опубликовано: (2001)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
по: Chelsea Baker, и др.
Опубликовано: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
по: Fournier, Marie, и др.
Опубликовано: (2014-10-01)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
по: Ammälä, C, и др.
Опубликовано: (1996)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
по: Geoffrey Hackett
Опубликовано: (2020-07-01)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
по: Misra, S, и др.
Опубликовано: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
по: Niki, I, и др.
Опубликовано: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
по: Proks, P, и др.
Опубликовано: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
по: Wendt, A, и др.
Опубликовано: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
по: Peter Proks, и др.
Опубликовано: (2018-01-01)

Should an echocardiographic scan be done routinely for infants of diabetic mothers?
по: M Vural, и др.
Опубликовано: (1995-10-01)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
по: Proks, P, и др.
Опубликовано: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
по: Hansen, A, и др.
Опубликовано: (2002)

To believe or not to believe
по: Chistine Kuruç
Опубликовано: (1989-12-01)

Continued Dispensing: what medications do patients believe should be available?
по: Salem Hasn Abukres, и др.
Опубликовано: (2015-05-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
по: Irina Arkad'evna Bondar, и др.
Опубликовано: (2015-03-01)

Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.
по: Reimann, F, и др.
Опубликовано: (1999)